Thelansis

 LAD II also recognized as a congenital disorder of glycosylation IIc (CDG IIc), is a rare congenital condition that disrupts the adhesion cascade's initial phase, specifically impeding selectin-mediated leukocyte tethering and rolling on the endothelium. Selectins adhere to glycoproteins or glycolipids adorned with fucosylated carbohydrate structures akin to sialyl Lewisx (sLex). LAD II leukocytes exhibit a near-complete lack of sLex expression, significantly impeding interactions with endothelial selectins and resulting in immunodeficiency. Furthermore, they do not express the H blood group antigen (Bombay phenotype) or the Lewis blood group antigens Lea and Leb, all of which are oligosaccharides containing a fucose unit, leading to the initial hypothesis that LAD II stems from a generalized defect in fucosylated structure biosynthesis. LAD II manifests with significantly elevated peripheral neutrophil counts, the cause of which remains elusive. One plausible explanation is the d...

 Leukocyte adhesion deficiency type II (LAD-II) is a form of LAD characterized by recurrent bacterial infections, severe growth delay, and severe intellectual deficit. LAD-II is a carbohydrate-deficient glycoprotein syndrome (CDG syndrome) and is therefore also referred to as CDG IIc. It results from mutations in the SLC35C1 gene (11p11.2), encoding the guanosine 5'-diphosphate (GDP)-fucose transporter localized in the Golgi apparatus. This is a specific fucose transporter that translocates GDP-fucose from the cytosol to the Golgi, where it is used as a substrate for fucosylation. Thelansis’s “Leukocyte Adhesion Deficiency Type II Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Ad...

  Leukocyte adhesion deficiency type II (LAD-II) is a form of LAD (see this term) characterized by recurrent bacterial infections, severe growth delay, and severe intellectual deficit.   Etiology- LAD-II is a carbohydrate-deficient glycoprotein syndrome (CDG syndrome) and is therefore also referred to as CDG IIc. It results from mutations in the SLC35C1 gene (11p11.2), encoding the guanosine 5'-diphosphate (GDP)-fucose transporter localized in the Golgi apparatus. This is a specific fucose transporter that translocates GDP-fucose from the cytosol to the Golgi where it is used as a substrate for fucosylation.   Epidemiology- LAD-II is extremely rare: less than 10 cases have been reported so far   The competitive landscape of Leukocyte Adhesion Deficiency Type II includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs...